AL164 / Alector - LARVOL DELTA

Recent Program Updates (GlobeNewswire) - "Alector continues to advance AL037/AL137...The company is targeting an IND submission in Q1 2027...Alector continues to advance AL064/AL164, its ABC-enabled tau siRNA program for the treatment of AD and other tauopathies....In addition to AL164, the company is advancing early-stage siRNA programs toward lead candidate selection, including ADP062-ABC, an alpha-synuclein siRNA for PD and ADP065-ABC, an NLRP3 siRNA for multiple neurodegenerative conditions, reflecting the broad applicability of the ABC platform across disease mechanisms."

IND • Pipeline update • Alzheimer's Disease • Parkinson's Disease